Related Experiment Video
Updated: Jan 10, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Checkpoint Inhibitor Pneumonitis: Key Insights for Pulmonologists
Candela Serra1, Mariana Benegas2, Xavier Alsina-Restoy3
1Department of Pulmonary Medicine, Consorci Hospitalari de Vic, 08500 Barcelona, Spain.
Immune checkpoint inhibitors (ICIs) can cause pneumonitis, a serious side effect. This review helps pulmonologists recognize and manage this potentially fatal complication for better patient outcomes.
Area of Science:
- Oncology
- Pulmonology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
- Immune-related adverse events (irAEs) are common, with pneumonitis being a significant concern due to its high mortality.
- Checkpoint inhibitor pneumonitis (CIP) presents with nonspecific symptoms, complicating diagnosis and management.
Purpose of the Study:
- To provide pulmonologists with a comprehensive overview of CIP.
- To enhance early detection and evidence-based management of pneumonitis in patients receiving ICIs.
- To consolidate current knowledge on CIP pathophysiology, risk factors, diagnosis, and treatment.
Main Methods:
- Narrative review of reported cases of pneumonitis in cancer patients treated with ICIs.
- Exploration of ICI mechanisms of action and the pathophysiology of pneumonitis.
- Analysis of clinical presentation, diagnostic strategies, and treatment approaches.
Main Results:
- Pneumonitis is a critical irAE associated with ICIs, requiring specialized pulmonologist involvement.
- Understanding ICI mechanisms is key to deciphering CIP pathophysiology.
- Early recognition and prompt management are crucial for mitigating CIP severity.
Conclusions:
- Pulmonologists play a vital role in diagnosing and managing CIP.
- A thorough understanding of CIP clinical presentation and diagnostic tools is essential.
- Evidence-based management strategies are critical for improving outcomes in patients with CIP.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: